Literature DB >> 23801354

Duration of postoperative intravenous antibiotics in childhood complicated appendicitis: a propensity score-matched comparison study.

Tzu-Chieh Yu1, James K M Hamill2, Stephen M Evans2, Neil R Price2, Philip N Morreau2, Vipul A Upadhyay2, R Stuart Ferguson2, Emma J Best3, Andrew G Hill1.   

Abstract

INTRODUCTION: Postoperative antibiotics complement surgery in managing childhood-complicated appendicitis. However, there is limited evidence to guide clinicians on appropriate duration of therapy. A comparison cohort study was performed to determine whether tailoring duration of inpatient intravenous (IV) antibiotic therapy to patient response, assessed using a set of clinical criteria, leads to shortened hospital length of stay (LOS) without compromising patient outcomes. PATIENTS AND METHODS: Over a 6-month period, 47 children (aged 5-14 years) with complicated appendicitis were treated with postoperative IV antibiotics until each satisfied a set of bedside clinical parameters suggesting resolved intraperitoneal infection (core temperature < 38°C for 24 hours, tolerated two consecutive meals, mobilizing independently, requiring only oral analgesia). Complicated appendicitis was defined as the presence of generalized peritonitis, appendiceal perforation or gangrene, and/or abscess. Postoperative recovery parameters were prospectively recorded and compared with those of 47 historical control patients, matched by propensity scores, who received 5 days minimum of postoperative IV antibiotics. Sample size was determined by a priori power calculation based on reduction in LOS. Severity of postoperative complications was graded using the Clavien-Dindo system.
RESULTS: Study group variables were comparable including patient demographics, duration of presenting symptoms, severity of presenting disease, preoperative antibiotics received, length of operation, seniority of primary surgeon, surgical approach taken, and intraoperative findings. The prospective cohort had a significantly shorter median LOS compared with the historical control cohort (5 vs. 6 nights, p = 0.010) while readmission rates and the incidence and severity of complications were similar, including incidence of postoperative intra-abdominal infections (6 vs. 8 cases, p = 0.562).
CONCLUSION: Using bedside clinical parameters indicative of resolved intraperitoneal infection to tailor duration of postoperative IV antibiotics for children with complicated appendicitis shortens LOS without apparent compromise to patient outcomes. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801354     DOI: 10.1055/s-0033-1349055

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  3 in total

Review 1.  ANTIBIOTICS FOR APPENDICECTOMY IN CHILDREN AND ADOLESCENTS DURING THE PERIOPERATIVE PERIOD: AN INTEGRATIVE REVIEW.

Authors:  Fátima Maria Castelo Branco Roque; Antônio Aldo Melo Filho; Alberto Jorge Castelo Branco Roque; Hanne Castelo Branco Roque; Thereza Maria Magalhães Moreira; Edna Maria Camelo Chaves
Journal:  Rev Paul Pediatr       Date:  2019-07-04

2.  Diagnosis and management of acute appendicitis. EAES consensus development conference 2015.

Authors:  Ramon R Gorter; Hasan H Eker; Marguerite A W Gorter-Stam; Gabor S A Abis; Amish Acharya; Marjolein Ankersmit; Stavros A Antoniou; Simone Arolfo; Benjamin Babic; Luigi Boni; Marlieke Bruntink; Dieuwertje A van Dam; Barbara Defoort; Charlotte L Deijen; F Borja DeLacy; Peter Mnyh Go; Annelieke M K Harmsen; Rick S van den Helder; Florin Iordache; Johannes C F Ket; Filip E Muysoms; M Mahir Ozmen; Michail Papoulas; Michael Rhodes; Jennifer Straatman; Mark Tenhagen; Victor Turrado; Andras Vereczkei; Ramon Vilallonga; Jort D Deelder; Jaap Bonjer
Journal:  Surg Endosc       Date:  2016-09-22       Impact factor: 4.584

3.  Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial.

Authors:  Anne Loes van den Boom; Elisabeth M L de Wijkerslooth; Joost van Rosmalen; Frédérique H Beverdam; Evert-Jan G Boerma; Marja A Boermeester; Joanna W A M Bosmans; Thijs A Burghgraef; Esther C J Consten; Imro Dawson; Jan Willem T Dekker; Marloes Emous; Anna A W van Geloven; Peter M N Y H Go; Luc A Heijnen; Sander A Huisman; Dayanara Jean Pierre; Joske de Jonge; Jurian H Kloeze; Marc A Koopmanschap; Hester R Langeveld; Misha D P Luyer; Damian C Melles; Johan W Mouton; Augustinus P T van der Ploeg; Floris B Poelmann; Jeroen E H Ponten; Charles C van Rossem; Wilhelmina H Schreurs; Joël Shapiro; Pascal Steenvoorde; Boudewijn R Toorenvliet; Joost Verhelst; Hendt P Versteegh; Rene M H Wijnen; Bas P L Wijnhoven
Journal:  Trials       Date:  2018-05-02       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.